Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program
Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program
09-03-2025
Event Details:
- FTI Preclinical Program Review: Synergistic Combinations with Targeted Therapies
Tuesday, September 16, 2025 1:30 p.m. PT /4:30 p.m. ET
This event will explore the scientific foundation, mechanisms of action and preclinical data supporting the combination of FTIs with tyrosine kinase inhibitors (TKIs), RAS inhibitors, and PI3K alpha inhibitors, highlighting their potential to transform treatment for solid tumors. - Discussion of Clinical Data Presented at 2025
ESMO Congress , Including First Clinical Data from KO-2806, Kura’s Next-Generation FTISaturday, October 18, 2025 10:30 a.m. PT /1:30 p.m. ET
This event will dive into clinical data presented at the 2025European Society for Medical Oncology (ESMO) Congress , including the first clinical insights from KO-2806, Kura’s next-generation FTI, showcasing its potential to address resistance mechanisms in cancer.
Live audio webcasts will be available in the Investors section of Kura’s website at https://kuraoncology.com/, with archived replays available following both events.
Details of the presentations at
Farnesyltransferase inhibitor (FTI) KO-2806 in combination with cabozantinib (cabo) in renal cell carcinoma (RCC): Preliminary results from FIT-001 phase 1 trial
Publication Number 2604P
A phase 1 study of the next-generation farnesyltransferase inhibitor (FTI) KO-2806 as monotherapy in advanced solid tumors
Publication Number 981P
Tipifarnib (TIP) and alpelisib (ALP) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 1 results from KURRENT-HN
Publication Number 1349P
The three posters presented at
About
Forward-Looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include, among other things, statements regarding the potential of FTIs to transform treatment for solid tumors and to address resistance mechanisms in cancer. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Kura may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings, and other interactions with regulatory bodies, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “promise,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Kura faces, please refer to Kura’s periodic and other filings with the
Contacts
Investors and media:
858-987-4046
gmann@kuraoncology.com
Source: Kura Oncology, Inc.